DEC 14, 2016 07:30 AM PST
Advances in modeling human diseases using induced pluripotent stem cell-derived cellular models
SPONSORED BY: Cellular Dynamics
7 15 3453

Speakers:
  • Field Application Scientist; Cellular Dynamics
    Biography
      T.K. Feaster, PhD, is a Field Application Scientist at Cellular Dynamics International (CDI; Madison, WI), a Fujifilm company. Dr. Feaster received his PhD in Pharmacology in 2015 from Vanderbilt University for his work using human induced pluripotent stem cell-derived cardiomyocytes to investigate cardiac excitation-contraction coupling. Dr. Feaster joined CDI as a Technical Application Scientist working in the applications group where he served as the primary support liaison for cardiac products, as well as sharing responsibility for in-lab application development. He is currently a Field Application Scientist for CDI's Toxicology and Safety Pharmacology business unit.
    • Applications Scientist; Cellular Dynamics
      Biography
        Kile P. Mangan, PhD, an Applications Scientist at CDI, achieved Bachelor degrees in both Physiological Psychology and Philosophy (2000), followed by a PhD in Neuroscience (2013) from the University of Wisconsin - Madison. Dr. Mangan previously worked at Kimberly-Clark Corp., Rush Medical Center and University of Wisconsin School of Medicine. Dr. Mangan's PhD thesis work centered on a genetic absence (R43Q) epilepsy, discovering that tonic inhibitory currents were abolished within excitatory principle cortical neurons via a mutation-induced GABAergic receptor-trafficking alteration. His research further uncovered a novel, synthetic steroid treatment to re-establish the lost tonic inhibition, thereby decreasing absence seizure episode number and severity. At CDI, his work includes all aspects of CDI's neuronal products, including electrophysiological behaviors and measurements. Dr. Mangan's evaluation on neural-network integration and maturation within iPSC-derived neuronal cultures has helped push the field of MEA analysis and pharmacological screening forward to ‘disease-in-a-dish' assays.

      Abstract:

      DATE: December 14, 2016
      TIME: 7:30am PT, 10:30am ET

      A major hurdle in developing relevant disease models for drug discovery is access to the healthy and diseased tissue of interest; induced pluripotent stem cell (iPSC) technology addresses this problem affording access to biologically relevant human tissues in essentially unlimited quantities. In this webinar, we will describe examples of how iPSC-derived disease cell models can be used to understand pathophysiological pathways in disease. Among the examples we will highlight are models of diseases induced in iPSC-derived cells from a healthy background; of epilepsy, Alzheimer’s and Parkinson’s diseases engineered into a healthy background; and of monogenic and idiopathic patient-derived models for cardiac diseases. We will briefly touch on current efforts aimed at generating large iPSC clone banks from disease backgrounds that will serve to expand access to human cell-based models. These human cell-based models can be used to explore the pathological phenotypes, genotype phenotype relationships, and environmental influences on a disease.


      Show Resources
      Loading Comments...